Qin, S., Li, Q., Gu, S., Chen, X., Lin, L., Wang, Z., Xu, A., Chen, X., Zhou, C., Ren, Z., Yang, L., Xu, L., Bai, Y., Chen, L., Li, J., Pan, H., Cao, B., Fang, W., Wu, W., Wang, G., Cheng, Y., Yu, Z., Zhu, X., Jiang, D., Lu, Y., Wang, H., Xu, J., Bai, L., Liu, Y., Lin, H., Wu, C., Zhang, Y., Yan, P., Jin, C., & Zou, J. (2021). apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet gastroenterology and hepatology, 6, 559–568. http://access.bl.uk/ark:/81055/vdc_100132727665.0x000003